News | April 15, 2024
Novartis tender offer for MorphoSys commences
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The company plans to add 1700 beds by FY27 through the organic route
Pharma Solutions operates 10 research and development and/or production sites globally
The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol
To accelerate the development of next-generation radioconjugates to treat cancer
The plan essentially was to separate Aster’s India and GCC businesses to unlock long-term value
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Dalal is an experienced leader at Abbott, having joined in 1995 as a Product Manager
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
ANVISA issues CGMP to Concord Biotech’s Unit I
Subscribe To Our Newsletter & Stay Updated
